机构名称：
¥ 2.0
• ARs requiring dosage interruption in ≥2.0% of patients who received KRAZATI included diarrhea, nausea, vomiting, abdominal pain, dizziness, headache, pneumonia, alanine aminotransferase increased, aspartate aminotransferase increased, dyspnea, fatigue, pleural effusion, rash, anemia, electrocardiogram QT延长，血液胆红素增加，血肌酐增加，食欲降低，脱水，出血，低磁性血症，脂肪酶增加，肌肉无力，肌肉无力，肌肉骨骼疼痛和去虫剂量降低，导致35％的患者
Krazati治疗管理指南
主要关键词
相关文件推荐
